解放军医学院学报Issue(4)：326-328,341,4.DOI:10.3969/j.issn.2095-5227.2015.04.007
埃克替尼与吉非替尼治疗表皮生长因子受体突变的晚期肺腺癌疗效观察
Efficacy of icotinib and gefitinib in advanced lung adenocarcinoma with EGFR mutation
崔瀚之 1管静芝 1廖国清 1刘鹏辉 1李亮亮 1邵艳1
作者信息
- 1. 解放军第309医院 肿瘤科，北京 100091
- 折叠
摘要
Abstract
Objective To investigate the clinical efficacy and toxicity of icotinib and gefitinib in advanced lung adenocarcinoma with EGFR mutation.Methods Clinical data about 56 patients with advanced lung adenocarcinoma admitted to our hospital from January 2012 to June 2014 were retrospectively analyzed. They were divided into icotinib group and gefitinib group randomly, and patients in icotinib group were treated with icotinib three times a day by 125 mg, patients in gefitinib group were treated with gefitinib once a day by 250 mg at least one month.Results In icotinib group, complete response (CR), partial response (PR), stable disease and progressive disease were achieved in 0, 11, 7 and 10 patients, respectively, with the objective response rate (ORR) of 39.3% and disease control rate (DCR) of 64.3%. In gefitinib group, complete response (CR), partial response (PR), stable disease and progressive disease were achieved in 0, 7, 8 and 13 patients, respectively, with the objective response rate (ORR) of 25% and disease control rate (DCR) of 53.6%. There was no significant difference between the two groups in ORR, DCR, TTP and OS. The main adverse reactions were rash and diarrhea, which were less occurred in icotinib group (P<0.05).ConclusionIcotinib and gefitinib have similar efficacy in advanced lung adenocarcinoma with EGFR mutation, however, the toxicity of icotinib is better tolerated and acceptable.关键词
埃克替尼/吉非替尼/晚期肺腺癌/不良反应Key words
icotinib/gefitinib/advanced lung adenocarcinoma/untoward reaction分类
医药卫生引用本文复制引用
崔瀚之,管静芝,廖国清,刘鹏辉,李亮亮,邵艳..埃克替尼与吉非替尼治疗表皮生长因子受体突变的晚期肺腺癌疗效观察[J].解放军医学院学报,2015,(4):326-328,341,4.
